Skip to main content

Adherence to Antiplatelet Therapy after Stent Implantation

1.4 Project
Endorsement Status
1.1 New or Maintenance
E&M Cycle
Is Under Review
1.3 Measure Description

Average proportion of days covered (PDC) for individuals with antiplatelet therapy during the 12 months following implantation of a coronary artery drug-eluting stent (DES) or a bare-metal stent (BMS).

        • 1.14 Numerator

          The sum of the days covered by the days’ supply of all antiplatelet prescriptions during the days measured in the denominator

        • 1.15 Denominator

          The sum of the days measured for all individuals who undergo a coronary artery drug-eluting stent (DES) or bare-metal stent (BMS) placement at any time during the first 12 months of the 24-month measurement period and have at least two prescriptions for antiplatelet therapy during the 12 months following stent placement

        • Exclusions

          Individuals with a history of contraindication(s) to antiplatelet therapy are excluded. Contraindications include peptic ulcer disease, intracranial hemorrhage, and gastrointestinal (GI) bleed.

        • Most Recent Endorsement Activity
          Measure Retired and Endorsement Removed Cardiovascular Spring Cycle 2018
          Initial Endorsement
          Last Updated
          Removal Date
        • Steward Organization Email
          Steward Organization Copyright

          Limited proprietary coding is contained in the measure specifications for user convenience. Use of these codes may require permission from the code owner or agreement to a license.

          ICD-10 codes are copyright © World Health Organization (WHO), Fourth Edition, 2010.